Selecting a CDMO for high-potency active pharmaceutical ingredient development requires more than checking whether a partner “handles HPAPIs”. Pharma and biotech teams need to understand whether the CDMO can combine formulation expertise, proven containment, analytical development, GMP manufacturing, cleaning validation […]
Selecting a Contract Development and Manufacturing Organisation (CDMO) for high-potency active pharmaceutical ingredient (HPAPI) small molecule formulation development requires a verification process that is fundamentally more rigorous than for standard compound programmes. The containment infrastructure, operator safety controls and Good […]
Adragos Pharma provides sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) services across three European manufacturing sites in France and Switzerland, supported by visual inspection and packaging capability in Japan. From early-phase clinical batches through to high-volume commercial supply, […]
Pharmaceutical semisolid and liquid manufacturing scale-up is not a larger version of the laboratory batch. It is the disciplined translation of formulation science, process understanding, equipment capability and GMP control into a repeatable commercial process. For development and manufacturing leaders, […]
Commercial sterile injectable manufacturing is not only a production activity. It is a patient safety commitment, a quality system test, and a supply continuity challenge happening at the same time. For pharma and biotech leaders, the most visible consequence of […]
Sterile injectable fill-finish is where CMC either protects patients and timelines, or quietly accumulates risk until it becomes a deviation, an investigation, or a regulatory delay. When we outsource to a European CDMO, the documentation set has to do two […]
Get notified on our latest news.
